Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions.

A defining hallmark of glioblastoma is altered tumor metabolism. The metabolic shift towards aerobic glycolysis with reprogramming of mitochondrial oxidative phosphorylation, regardless of oxygen availability, is a phenomenon known as the Warburg effect. In addition to the Warburg effect, glioblastoma tumor cells also utilize the tricarboxylic acid cycle/oxidative phosphorylation in a different capacity than normal tissue. Altered metabolic enzymes and their metabolites are oncogenic and not simply a product of tumor proliferation. Here we highlight the advantages of why tumor cells, including glioblastoma cells, require metabolic reprogramming and how tumor metabolism can converge on tumor epigenetics and unanswered questions in the field.

[1]  Shichun Zheng,et al.  Pyruvate Kinase M2 Expression, but Not Pyruvate Kinase Activity, Is Up-Regulated in a Grade-Specific Manner in Human Glioma , 2013, PloS one.

[2]  H. Shime,et al.  IL-23-dependent and -independent enhancement pathways of IL-17A production by lactic acid. , 2011, International immunology.

[3]  D. Burk,et al.  On respiratory impairment in cancer cells. , 1956, Science.

[4]  T. Noguchi,et al.  Regulation of pyruvate kinase M gene expression. , 1999, Biochemical and biophysical research communications.

[5]  S. Mazurek.  Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. , 2011, The international journal of biochemistry & cell biology.

[6]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[7]  R. Deberardinis,et al.  Acetate Is a Bioenergetic Substrate for Human Glioblastoma and Brain Metastases , 2014, Cell.

[8]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[9]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[10]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[11]  Daniel J Brat,et al.  Pseudopalisades in Glioblastoma Are Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell Population , 2004, Cancer Research.

[12]  T. Tanaka,et al.  The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. , 1986, The Journal of biological chemistry.

[13]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[14]  P. Oefner,et al.  Lactic Acid and Acidification Inhibit TNF Secretion and Glycolysis of Human Monocytes , 2009, The Journal of Immunology.

[15]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[16]  G. Zadeh,et al.  Serum lactate as a potential biomarker of malignancy in primary adult brain tumours , 2015, Journal of Clinical Neuroscience.

[17]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[18]  R. Deberardinis,et al.  Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. , 2012, Cell metabolism.

[19]  Jie Li,et al.  PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells , 2013, Cell.

[20]  S. Wakil,et al.  Studies on the mechanism of fatty acid synthesis. I. Preparation and purification of an enzymes system for reconstruction of fatty acid synthesis. , 1957, Biochimica et biophysica acta.

[21]  Eric C. Holland,et al.  Gliomagenesis: genetic alterations and mouse models , 2001, Nature Reviews Genetics.

[22]  W Cramer,et al.  On the Origin of Cancer* , 1938, British medical journal.

[23]  A. Davison.  Basic Neurochemistry: Molecular, Cellular, and Medical Aspects , 1989 .

[24]  Jason W. Locasale,et al.  Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses , 2011, Science.

[25]  John L Cleveland,et al.  Targeting lactate metabolism for cancer therapeutics. , 2013, Journal of Clinical Investigation.

[26]  D. Brat,et al.  Malignant Glioma Physiology: Cellular Response to Hypoxia and Its Role in Tumor Progression , 2003, Annals of Internal Medicine.

[27]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[28]  Steven Eschrich,et al.  The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. , 2012, Cancer research.

[29]  E. Hafen,et al.  Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. , 2003, Molecular cell.

[30]  William J. Israelsen,et al.  ML265: A potent PKM2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model , 2013 .

[31]  I. Pollack,et al.  Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas , 2009, International journal of cancer.

[32]  S. Moncada,et al.  The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C–Cdh1 , 2009, Nature Cell Biology.

[33]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[34]  J. Hoek,et al.  Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. , 2005, Cancer research.

[35]  H. Christofk,et al.  Pyruvate kinase M2 is a phosphotyrosine-binding protein , 2008, Nature.

[36]  G. Semenza,et al.  Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1* , 1996, The Journal of Biological Chemistry.

[37]  P. Kleihues,et al.  Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.

[38]  A. Guha,et al.  Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme , 2011, Neurobiology of Disease.

[39]  J. Tavaré,et al.  The Identification of ATP-citrate Lyase as a Protein Kinase B (Akt) Substrate in Primary Adipocytes* , 2002, The Journal of Biological Chemistry.

[40]  W. Cavenee,et al.  Heterogeneity maintenance in glioblastoma: a social network. , 2011, Cancer research.

[41]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[42]  Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme , 2011 .

[43]  P. Srere.  The citrate cleavage enzyme. I. Distribution and purification. , 1959, The Journal of biological chemistry.

[44]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  B. Dwarakanath,et al.  Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. , 1996, International journal of radiation oncology, biology, physics.

[46]  Matthew K. Knabel,et al.  Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1 , 2011, Cell.

[47]  Pierre Sonveaux,et al.  Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. , 2011, Cancer research.

[48]  J. Uhm.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .

[49]  J. Testa,et al.  Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells , 2005, Oncogene.

[50]  A. Guha,et al.  Mouse Models to Interrogate the Implications of the Differentiation Status in the Ontogeny of Gliomas , 2011, Oncotarget.

[51]  J. Menéndez,et al.  Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis , 2007, Nature Reviews Cancer.

[52]  J. Bussink,et al.  Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4 , 2011, BMC Cancer.

[53]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[54]  C. Thompson,et al.  ATP citrate lyase is an important component of cell growth and transformation , 2005, Oncogene.

[55]  M. Dewhirst,et al.  Targeting the Lactate Transporter MCT1 in Endothelial Cells Inhibits Lactate-Induced HIF-1 Activation and Tumor Angiogenesis , 2012, PloS one.

[56]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[57]  L. Wenchao,et al.  The mTOR Inhibitor Rapamycin Synergizes with a Fatty Acid Synthase Inhibitor to Induce Cytotoxicity in ER/HER2-Positive Breast Cancer Cells , 2014, PloS one.

[58]  S. Kornbluth,et al.  Fatty Acid Synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death , 2014, Oncogene.

[59]  Rameen Beroukhim,et al.  Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. , 2011, Cancer discovery.

[60]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[61]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[62]  R. Wittig,et al.  Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas. , 2008, American journal of clinical pathology.

[63]  S. Marshall,et al.  Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. , 1991, The Journal of biological chemistry.

[64]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[65]  E. Kandel,et al.  Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. , 2001, Genes & development.

[66]  D. Lin,et al.  Malignancy-associated metabolic profiling of human glioma cell lines using 1H NMR spectroscopy , 2014, Molecular Cancer.

[67]  F. Sotgia,et al.  Autophagy drives compartment‐specific oncogenesis: HIF1‐alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells , 2011 .

[68]  P. Kleihues,et al.  Definition of Primary and Secondary Glioblastoma—Response , 2014, Clinical Cancer Research.

[69]  J. Mackey,et al.  Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer , 2008, British Journal of Cancer.

[70]  Gregor Rothe,et al.  Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.

[71]  Sébastien Bonnet,et al.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.

[72]  K. Wellen,et al.  Cellular metabolic stress: considering how cells respond to nutrient excess. , 2010, Molecular cell.

[73]  R. Deberardinis,et al.  Metabolism of [U‐13C]glucose in human brain tumors in vivo , 2012, NMR in biomedicine.

[74]  M. Flentje,et al.  Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[75]  Ralph J Deberardinis,et al.  Brick by brick: metabolism and tumor cell growth. , 2008, Current opinion in genetics & development.

[76]  Christian M. Metallo,et al.  Metabolic pathway alterations that support cell proliferation. , 2011, Cold Spring Harbor symposia on quantitative biology.

[77]  Pierre J Magistretti,et al.  Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. , 2011, Cell metabolism.

[78]  A. Mackensen,et al.  Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. , 2006, Blood.

[79]  D. Sabatini,et al.  SHMT2 drives glioma cell survival in the tumor microenvironment but imposes a dependence on glycine clearance , 2015 .

[80]  A. Halestrap,et al.  The Plasma Membrane Lactate Transporter MCT4, but Not MCT1, Is Up-regulated by Hypoxia through a HIF-1α-dependent Mechanism* , 2006, Journal of Biological Chemistry.

[81]  R. Deberardinis,et al.  The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. , 2007, Genes & development.

[82]  M. Tan,et al.  Targeting cellular metabolism to improve cancer therapeutics , 2013, Cell Death and Disease.

[83]  Abhishek K. Jha,et al.  Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. , 2013, Cancer cell.

[84]  P. Mischel,et al.  Metabolic state of glioma stem cells and nontumorigenic cells , 2011, Proceedings of the National Academy of Sciences.

[85]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[86]  H. Shime,et al.  Tumor-Secreted Lactic Acid Promotes IL-23/IL-17 Proinflammatory Pathway1 , 2008, The Journal of Immunology.

[87]  Nicolò Riggi,et al.  Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. , 2012, Genes & development.

[88]  Christian M. Metallo,et al.  Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis , 2012, Nature chemical biology.

[89]  Elisabet Cuyàs,et al.  Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells , 2014, Oncotarget.

[90]  J. Hoek,et al.  Mitochondrial Binding of Hexokinase II Inhibits Bax-induced Cytochrome c Release and Apoptosis* , 2002, The Journal of Biological Chemistry.

[91]  Sutapa Banerjee,et al.  Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner , 2011, Proceedings of the National Academy of Sciences.

[92]  D. Sabatini,et al.  Nutrient-sensing mechanisms and pathways , 2015, Nature.

[93]  Jill S Barnholtz-Sloan,et al.  Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution , 2015, Genome research.

[94]  M. V. Vander Heiden,et al.  Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. , 2011, Annual review of cell and developmental biology.

[95]  B. Kefas,et al.  Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. , 2010, Neuro-oncology.

[96]  Sami I. Horih.  Basic Neurochemistry , 1989, Neurology.

[97]  John Eric Wilson,et al.  Coordinated regulation of cerebral glycolytic and oxidative metabolism, mediated by mitochondrially bound hexokinase dependent on intramitochondrially generated ATP. , 1992, Archives of biochemistry and biophysics.

[98]  Robert J Dempsey,et al.  Science Times , 2022 .

[99]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[100]  J. Blenis,et al.  Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb , 2003, Current Biology.

[101]  L. Parada,et al.  The Molecular and Genetic Basis of Neurological Tumours , 2002, Nature Reviews Cancer.

[102]  V. P. Collins,et al.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.

[103]  J. Mackey,et al.  Metabolic Modulation of Glioblastoma with Dichloroacetate , 2010, Science Translational Medicine.

[104]  F. Apiou,et al.  High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. , 1996, British Journal of Cancer.

[105]  A. Alavi,et al.  Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.

[106]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[107]  Yuan Qi,et al.  Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Citation Verhaak , 2010 .

[108]  F. Sotgia,et al.  HIF1-alpha functions as a tumor promoter in cancer-associated fibroblasts, and as a tumor suppressor in breast cancer cells , 2010, Cell cycle.

[109]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[110]  O. Warburg.  On the origin of cancer cells. , 1956, Science.

[111]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[112]  S. Ochoa,et al.  Enzymatic synthesis of citric acid. V. Reaction of acetyl coenzyme A. , 1952, The Journal of biological chemistry.

[113]  Li-Ju Chang,et al.  Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. , 2014, Cell reports.

[114]  S J Remington,et al.  Citrate synthase: structure, control, and mechanism. , 1986, Annual review of biophysics and biophysical chemistry.

[115]  H. Kung,et al.  JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1α–mediated glucose metabolism , 2013, Proceedings of the National Academy of Sciences.

[116]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[117]  T. Lazar Mathew,et al.  Optimizing Cancer Radiotherapy with 2-Deoxy-D-Glucose , 2005, Strahlentherapie und Onkologie.

[118]  G. Yi,et al.  ATP citrate lyase inhibitors as novel cancer therapeutic agents. , 2012, Recent patents on anti-cancer drug discovery.